(Total Views: 530)
Posted On: 04/09/2021 9:09:16 AM
Post# of 145247
Someone came to a conclusion, is it the correct one? What we do know is that symptoms are heterogeneous and biomarkers are quite varied . It may only be a phase 2 trial but with only 25 patients in the drug arm it will be much harder to establish the best protocol than if there were more patients.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)